Evidence map›Paper›PMID 42324826›Full record

ReviewVirulence2026

The current landscape and future directions of Lyme disease vaccines.

Zhiqiang Chen, Ling He, Xun Huang, Xiao Liang, Aihua Liu, Fukai Bao

Abstract readReview
In one paragraph

Review in Virulence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhiqiang ChenYunnan Province Key Laboratory of Children's Major Diseases Research, Department of Pathogen Biology and Immunology, Faculty of Basic Medicine, Kunming Medical University, Kunming, China.ORCID 0009-0002-0725-812X
Ling HeDepartment of Science and Education, People's Hospital of Fengjie, Chongqing, People's Republic of China.
Xun HuangYunnan Province Key Laboratory of Children's Major Diseases Research, Department of Pathogen Biology and Immunology, Faculty of Basic Medicine, Kunming Medical University, Kunming, China.
Xiao LiangYunnan Province Key Laboratory of Children's Major Diseases Research, Department of Pathogen Biology and Immunology, Faculty of Basic Medicine, Kunming Medical University, Kunming, China.
Aihua LiuYunnan Province Key Laboratory of Children's Major Diseases Research, Department of Pathogen Biology and Immunology, Faculty of Basic Medicine, Kunming Medical University, Kunming, China.
Fukai BaoYunnan Province Key Laboratory of Children's Major Diseases Research, Department of Pathogen Biology and Immunology, Faculty of Basic Medicine, Kunming Medical University, Kunming, China.ORCID 0000-0003-2652-6660

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lyme disease (LD) represents a significant public health challenge in North America and Eurasia. The persistent increase in its incidence may create an opportunity for vaccines to gain broader acceptance. Recent years have seen notable advances in vaccine development. However, achieving a balance between broad-spectrum protection and durable immunity remains a critical bottleneck. This article is presented as a narrative review that systematically summarizes recent progress in Lyme disease vaccine research worldwide, with particular emphasis on the strengths and limitations of approved and investigational candidates. Unlike existing reviews, this study integrates recent clinical investigations of multivalent vaccine candidates with breakthrough advances across diverse vaccine platforms, yielding a comprehensive and current synthesis. We identify critical challenges in contemporary vaccine development and propose actionable solutions. Our forward-looking perspective centers on a triangular strategy that integrates antigen multivalency, platform personalization, and geographical customization, providing a conceptual framework to guide future LD immunoprophylaxis research.

Indexed as

Lyme DiseaseLyme Disease VaccinesVaccine DevelopmentAnimalsBorrelia burgdorferiHumansLyme Disease VaccinesBorrelia burgdorferi sensu latoLyme diseasepublic healthvaccine

Identifiers

PMID42324826
PMCPMC13290084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.